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1. Introduction 
Mucosal injury remains an undesirable, painful, and expensive side effect of cytotoxic 
cancer therapy and is disheartening for patients and frustrating for caregivers.[1,2] Mucositis 
and associated outcomes in patients receiving radiotherapy (RT) for head and neck cancer 
shows that the mean incidence was 80%.[3] Rates of hospitalization due to mucositis are 
reported to be 16% overall and 32% for RT-AF (altered fraction radio therapy) patients.[3 
Patients in the high risk of developing oral mucositis group fall into the head and neck 
cancer population where the incidence of mucositis is high in this group.[3] 
Oral mucositis is a distressing toxic effect of chemotherapy and radiotherapy. It can increase 
the need for total parenteral nutrition and opioids analgesics, prolong hospital stays, 
increase the risk of infection, and greatly affect the patient’s quality of life [4]. All patients 
treated with high-dose chemotherapy requiring hematopoietic stem cell or bone marrow 
transplantation develop oral mucositis of varying severity. In addition, up to 80% of patients 
receiving radiotherapy for head or neck tumours and almost 90% of pediatric patients 
treated for cancer also develop oral mucositis[5,6] 
2. Mechanism of development 
Radiation induced mucositis is initiated by direct injury to basal epithelial cells and cells in 
the underlying tissue. DNA-strand breaks can result in cell death or injury. Non-DNA injury 
is initiated through a variety of mechanisms, some of which are mediated by the generation 
of reactive oxygen species. Radiation and chemotherapy are effective activators of several 
injury-producing pathways in endothelia, fibroblasts, and epithelia. In these cells, the 
activation of transcription factors such as nuclear factor-κB (NF-κB) and NRF-2 leads to the 
upregulation of genes that modulate the damage response. Immune cells (macrophages) 
produce pro-inflammatory cytokines, such as tumor-necrosis factor-α (TNF-α) and 
interleukin-6, which causes further tissue injury.[7] These signaling molecules also 
participate in a positive-feedback loop that amplifies the original effects of radiation and 
chemotherapy. For example, TNF-α activates NF-κB and sphingomyelinase activity in the 
mucosa, leading to more cell death. In addition, direct and indirect damages to epithelial 
stem cells result in a loss of renewal capacity. As a result, the epithelium begins to thin and 
patients start to experience the early symptoms of mucositis.[8] 
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An oropharyngeal epithelial surface has a rapid rate of cell turnover and appears to be at 
high risk of injury from ionizing radiation. A healthy oral mucosa serves to clear 
microorganism and provides a chemical barrier that limits penetration of many compounds 
into the epithelium. A damaged mucosal surface increases the risk of a secondary infection. 
Acute mucositis results from the loss of squamous epithelial cells owing to the sterilization 
of mucosal stem cells and the inhibition of transit cell proliferation. This leads to a gradual 
linear decrease in epithelial cell numbers. Normally, cells of the mouth undergo rapid 
renewal over a 7–14 day cycle. Radiation therapy interferes with cellular mitosis and 
reduces the ability of the oral mucosa to regenerate. [9] 
As radiation therapy continues, a steady state between mucosal cell death and regeneration 
may occur because of an increased cell production rate from the surviving cells. Usually, 
however, cell regeneration cannot keep up with cell death, and therefore, partial or complete 
denudation develops. This presents as patchy or confluent mucositis. As the mucositis 
becomes more severe, pseudomembranes and ulceration develops. Poor nutritional status 
further interferes with mucosal regeneration by decreasing cellular migration and renewal. 
The loss of the epithelial barrier enhances insults from physical, chemical, and microbial 
agents. 
Stages of mode l[10] for the pathogenesis of mucositis are based on the evidence available to 
date: 
1. Initiation of tissue injury: Radiation and/or chemotherapy induce cellular damage 
resulting in death of the basal epithelial cells. The generation of reactive oxygen species 
(free radicals) by radiation or chemotherapy is also believed to exert a role in the 
initiation of mucosal injury. These small highly reactive molecules are by-products of 
oxygen metabolism and can cause significant cellular damage. 
2. Up-regulation of inflammation via generation of messenger signals: In addition to 
causing direct cell death, free radicals activate second messengers that transmit signals 
from receptors on the cellular surface to the inside of cell. This leads to up-regulation of 
pro-inflammatory cytokines, tissue injury, and cell death. 
3. Signaling and amplification: Up-regulation of pro-inflammatory cytokines, such as 
TNF-a, produced mainly by macrophages, causes injury to mucosal cells, and also 
activates molecular pathways that amplify mucosal injury. 
4. Ulceration and inflammation: There is a significant inflammatory cell infiltrate 
associated with the mucosal ulcerations, based in part on metabolic by-products of the 
colonizing oral microflora. Production of pro-inflammatory cytokines is also further up-
regulated as a result of this secondary infection.[10] 
5. Healing: This phase is characterized by epithelial proliferation, as well as, cellular and 
tissue differentiation,[11] restoring the integrity of the epithelium. 
A number of authors have reported that the oropharyngeal flora may contribute to 
radiation-induced mucositis. In health, the oral mucosa has a number of distinct habitats 
which are colonized by micro-organism that are able to establish a homeostatic 
community.[12] These homeostatic microbial communities are protective for the host by 
preventing or interfering with the colonization of exogenous pathogens; this potent defense 
mechanism is called “colonization resistance”. When the oral tissues are irradiated, the 
colonization resistance is practically abolished. Irradiation mucositis is caused by a 
combination of alteration of the normal oral microflora with concomitant changes in the 
tissues. However, healing eventually occurs when cells regenerate from the surviving 
mucosal stem cells. 
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3. Clinical presentation 
Clinically, mucositis presents with multiple complex symptoms. It begins with a 
symptomatic redness and erythema and progresses through solitary white elevated 
desquamative patches that are slightly painful to contact pressure. Following this, large, 
painful contiguous pseudo membranous lesions develop with associated dysphagia and 
decreased oral intake. The nonkeratinized mucosa is the most affected one. The most 
common sites include the labial, buccal, and soft palate mucosa, as well as, the floor of the 
mouth and the ventral surface of the tongue. Oral lesions usually heal within two to three 
weeks [Figure 1]. 
 
 
Fig. 1. Oral mucositis in a patient. 
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Mucositis is an inevitable side effect of radiation. Its severity is dependent on the type of 
ionizing radiation, the volume of irradiated tissue, the dose per day, and cumulative dose. It 
has been noted in a considerable number of clinical trials that the severity of acute normal 
tissue responses, particularly oral mucositis, is significantly increased when the overall 
treatment time is shortened.[12,13] The clinical course of oral mucositis may sometimes be 
complicated by local infection, particularly in immunosuppressed patients. Viral infections 
such as herpes simplex virus (HSV), and fungal infections such as candidiasis can 
sometimes be superimposed on oral mucositis. Although HSV infections do not cause oral 
mucositis, they can complicate its diagnosis and management. 
Histopathologically, edema of the retepegs is noted, along with vascular changes that 
demonstrate a thickening of the tunica intima with concomitant reduction in the lumen size 
and destruction of the elastic and muscle fibers of the vessel walls. The loss of the epithelial 
cells to the basement membrane exposes the underlying connective tissue stroma with its 
associated innervations, which, as the mucosal lesions enlarge, contributes to increasing 
pain. If the patient develops both severe mucositis and thrombocytopenia, oral bleeding 
may occur, which is very difficult to treat. 
4. Clinical management of oral mucositis 
Management of oral mucositis can be divided into the following sections: pain control, 
nutritional support, oral decontamination, palliation of dry mouth, management of oral 
bleeding, and therapeutic interventions for oral mucositis. 
4.1 Pain control 
The most common symptom of oral mucositis is pain. Pain significantly affects the 
nutritional intake, the mouth care, and the quality of life. Thus, management of mucositis 
pain is a primary component of any mucositis management strategy. Many centers use 
saline mouth rinses, ice chips, and topical mouth rinses containing an anesthetic, such as 2% 
viscous lidocaine, which may be mixed with equal volumes of diphenhydramine and a 
soothing covering agent in equal volumes. Such topical anesthetic agents may provide 
short-term relief. Sucralfate is the most commonly used and widely studied, even though 
there is no significant decrease in the pain control.[14,15] In addition to the use of topical 
agents, most patients with severe mucositis require systemic analgesics, often including 
opioids, for satisfactory pain relief. Though, the so called ‘magic mouthwash’ (lidocaine, 
diphenhydramine, magnesium aluminum hydroxide) has been observed to be beneficial, 
morphine mouth washes are preferable.[16,17] It was significantly better at reducing intensity 
and duration of pain and functional impairment, with fewer adverse effects. 
4.1.1 Sucralfate 
Sucralfate also has been tested in patients receiving radiation therapy. One study compared 
21 patients who received standard oral care to the head and neck with 24 patients who 
received sucralfate suspension four times daily. Results revealed a significant difference in 
mucosal edema, pain, dysphagia, and weight loss in patients receiving sucralfate [18]. In a 
pilot study done by Pfeiffer et al. [19], sequential patients who received radiation therapy to 
the head and neck received sucralfate at the onset of mucositis. Most patients had a decrease 
in pain following the use of sucralfate. A double-blind, placebo-controlled study with 
sucralfate in 33 patients who received. irradiation to the head and neck reported no 
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stastitically significant differences in mucositis; however, the sucralfate group reported less 
oral pain, and other topical and systemic analgesics were started later in the course of 
radiation [20]. A prospective double-blind study compared the effectiveness of sucralfate 
suspension versus diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced 
mucositis. Data were collected daily, including perceived pain, helpfulness of mouth rinses, 
weekly mucositis grade, weight change, and interruption of therapy. Analysis of the two 
groups revealed no statistically significant differences between the two groups. In a 
retrospective review, 15 patients who had not used daily oral rinses were compared with the 
two groups, and the results suggested that the use of a daily oral rinse with a mouth-coating 
agent may result in less pain, reduce weight loss, and help prevent interruption of radiation 
because of severe mucositis[21]. 
 
 
Fig. 2. Oral mucositis in a patient. 
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4.1.2 Morphine in pain control 
In a study to compare the effect of locally applied morphine mouthwash(MO) with Magic 
mouth wash (MG) on mucositis-related oral pain and on the maintenance of oral intake in 
patients with tumors of the head and neck area treated with a chemoradiotherapy 
regimen51. Additional objectives were to evaluate the safety of MO by determining the 
frequency of treatment-emergent drug-related adverse events (local and systemic) or 
hematologic and biochemical abnormalities, the intensity of chemoradiotherapy 
administered, tumor response, weight loss, need of a nasogastric tube, and mucositis-related 
hospitalizations. The duration of severe pain was 3.5 days less in the Morphine group 
compared with the Magic mouth wash group (P _ 0.032). The intensity of oral pain was also 
significantly lower in the MO group compared with the MG group .More patients in the MG 
group needed supplementary (oral or parenteral) analgesia compared with the MO group  
(P _ 0.019). Nevertheless, the time elapsed before the first supplemental analgesic and the 
total amount of analgesics taken was similar for both groups. Of 12 patients in the MG 
group, 3 (25%) and none in the MO group required third-step opiates for alleviation of 
mouth pain. However, the differences in the maximum WHO step needed for control of 
pain were not statistically significant. There was a significant difference in duration of 
severe functional impairment. Nevertheless, the body weight change was similar for both 
groups. There were no significant differences in documented or highly suspected infections, 
change in performance status, tumor response rate, and intensity of the chemoradiotherapy 
delivered between the two treatment groups. No patients required hospitalization due to 
mucositis during the study. Patients in the MG group reported more local side effects [51]. 
4.2 Nutritional support 
A soft diet or liquid diet was more easily tolerated than a normal diet, when oral mucositis 
is present; gastrostomy tube is more beneficial, when there is severe mucositis. 
4.3 Selective oral decontamination 
It has been hypothesized that microbial colonization of oral mucositis lesions exacerbates 
the severity of oral mucositis and, therefore, decontamination may help to reduce mucositis. 
Due to the fact that the oral cavity contains a high amount of Gram-negative bacilli and 
considering its etiological role in mucositis, the concept of ‘Selective Decontamination’ has 
been developed. In this regard, lozenges composed of polymyxin E, tobramycin, and 
amphotericin B have been studied in patients receiving radiation for cancers of head and 
neck in a randomized trial that compared lozenges with placebo or chlorhexidine rinses, the 
antimicrobial lozenges provided more effective mucositis prevention in patients receiving 
head and neck irradiation. Addition of ciprofloxacin or ampicillin with clotrimazole to 
Sucralfate has shown reduction in mucositis.[22] 
4.4 Oral hygiene 
Significant reduction in oral mucositis can be attained by proper oral hygiene measures.[23] It 
was noted that proper oral care also reduced oral toxicity of radiation therapy. Indeed, 
multiple studies have demonstrated that maintenance of good oral hygiene can reduce the 
severity of oral mucositis. Furthermore, oral decontamination can reduce infection of the 
oral cavity by opportunistic pathogens.[24] Therefore, a second function of oral 
decontamination can be to reduce the risk of systemic sepsis from resident oral and/or 
opportunistic pathogens. Intensive oral care protocol decreased risk of oral mucositis, but 
not the percentage of patients with a documented septicemia.[25] 
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The RTOG and MASCC/ISOO (Mucositis study group of the multinational association for 
supportive care in cancer and the International society of oral oncology) guidelines 
recommend use of a standardized oral care protocol, including brushing with a soft 
toothbrush, flossing, and the use of nonmedicated rinses (for example, saline or sodium 
bicarbonate rinses). Patients and caregivers should be educated regarding the importance of 
effective oral hygiene [26, 52, 53]. 
4.5 Palliation of dry mouth 
In cancer therapy, patients often develop transient or permanent xerostomia and 
hyposalivation. Hyposalivation can further aggravate inflamed tissues, increase risk for 
local infection, and make mastication difficult. Many patients also complain of a thickening 
of salivary secretions, because of a decrease in the serous component of saliva. The 
following measures can be taken for palliation of a dry mouth: 
 Sip water as needed to alleviate mouth dryness; several supportive products including 
artificial saliva are available. 
 Rinse with a solution of half a teaspoon of baking soda half in one cup warm water 
several times a day to clean and lubricate the oral tissues and to buffer the oral 
environment. 
 Chew sugarless gum to stimulate salivary flow. 
 Use cholinergic agents as necessary. 
4.6 Kaolin pectin 
Kaolin pectin, combined with diphenhydramine, which is a H1-histamine antagonist and 
local anesthetic, was found to reduce oral pain without reducing the degree of mucositis in a 
double blind randomized and controlled study.[27] 
5. Growth factors 
One of the problem faced by the therapy is the loss of proliferation of the oral epithelial cells, it 
has seen that various growth factors that can increase epithelial cell proliferation have been 
studied for the management of oral mucositis. Recent evidence shows that intravenous 
recombinant human keratinocyte growth factor-1, Palifermin, significantly reduced incidence 
of WHO grades 3 and 4 oral mucositis in patients with hematologic malignancies (for example, 
lymphoma and multiple myeloma) receiving high-dose chemotherapy and total body 
irradiation before autologous hematopoietic cell transplantation.[28]  
Human keratinocyte growth factor-2, Repifermin, was found to be ineffective in reducing 
the percentage of subjects who experienced severe mucositis.[29] Intravenous human 
fibroblast growth factor-20, Velafermin, is currently in clinical development for reduction of 
mucositis secondary to high-dose chemotherapy in autologous hematopoietic cell transplant 
patients.[30] The safety of this class of growth factors has not been established in patients 
with nonhematologic malignancies. There is a theoretical concern that these growth factors 
may promote growth of tumor cells, which may have receptors for the respective growth 
factor. However, one recent study found no significant difference in survival between 
subjects with colorectal cancer receiving Palifermin or placebo at a median follow-up 
duration of 14.5 months.[31] Further studies are ongoing to confirm the safety of epithelial 
growth factors in the solid tumor setting, including patients receiving radiation therapy for 
head and neck cancer. 
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Source Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
 WHO No change Soreness/erythema 
Erythema,ulcers, 
can eat solids 
Ulcers; requires liquid 
diet only 
Alimentation not 
possible 
RTOG 
No change 
over baseline 
May experience mild 
pain not requiring 
analgesic 
Patchy mucositis may 
have a serosanguinous 
discharge. May 
experience pain 
requiring analgesics.         
< 1.5 cm, 
noncontiguous   
Confluent fibrinous 
mucositis/may include 
severe pain requiring 
narcotics,           > 1.5 cm, 
contiguous 
Necrosis or 
deep 
ulceration, 
± bleeding . 
NCI CTC None 
Painless ulcers, 
erythema or mild 
soreness 
Painful 
erythema,oedema or 
ulcers, but can eat. 
 painful erythema, 
edema or ulcers  can not 
eat. 
Requires Parenteral or 
enteral support  
Van der 
schueren et al  
None Slight erythema Pronounced erythema Spotted mucositis 
Confluent mucositis 
patches >0.5cm. 
Byfield et al  --- 
Minimal dysphasia, 
thinning but no overt 
break in mucosal 
integrity. 
Significant dysphasia, 
semi soft foods only, 
focal mucosal vesicles or 
denuded patches. 
Fluids only tolerated, 
obviously large 
confluent patches of 
mucosal denudation  
Parenteral fluids only, 
severe confluent mucosal 
denudation with 
bleeding. 
Seto et al  ----- 
Localized erythema 
with no pain 
Generalized erythema 
without pain or 
localized erythema or 
ulcers with mild pain. 
Multiple ulcers or 
generalized erythema 
with moderate pain 
Generalized erythema or 
ulcers with moderate to 
severe pain. 
Eilers et al   ----- Pink and moist 
Reddened or white film 
without ulcerations 
Ulceration with or 
without bleeding 
 ------- 
NCIC None  
Painless 
ulcers,erythema,or 
mild soreness. 
Painful 
erythema,oedema,or 
ulcers, but can eat 
Painful 
erythema,oedema,or 
ulcers, but can not eat 
Mucosal necrosis and/or 
requires Parenteral or 
enteral 
support,dehydration. 
Spijkervet et al  None  White discoloration  Erythema Pseudomembrane ulceration 
Maceijewski  None  
Type: mild 
erythematous area: 
<25% 
Type : severe 
erythematous area: 25-
50% 
Type: spotted mucositis 
area >50% 
Type:confluent 
mucosistis 
Hickey et al  No stomatitis 
Whitish gingival or 
slight  burning 
sensation or 
discomfort. 
Moderate erythema and 
ulcerations or white 
patches.pain, but can 
eat, drink and swallow. 
severe erythema and 
ulcerations or white 
patches. Severe Pain and 
can not  eat, drink or 
swallow. 
------- 
Table 1. Comparison of commonly used mucositis scoring system 
6. Anti-inflammatory agents 
6.1 Benzydamine hydrochloride  
It is a nonsteroidal antiinflammatory drug that inhibits proinflammatory cytokines 
including TNF-a. In a Phase III trial, Benzydamine hydrochloride mouthrinse reduced the 
severity of mucositis in patients with head and neck cancer undergoing radiation therapy of 
cumulative doses up to 50-Gy radiation therapy.[32] Based on this and previous studies, the 
MASCC/ISOO guidelines recommends use of this agent in patients receiving moderate-
dose radiation therapy.[33] 
6.2 Saforis 
It is a proprietary oral suspension of L-glutamine that enhances the uptake of this amino acid into 
epithelial cells. Glutamine may reduce mucosal injury by reducing the production of 
proinflammatory cytokines and cytokine-related apoptosis;[34,35] and may promote healing by 
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increasing fibroblast and collagen synthesis.[36] In a Phase III study, this topical agent reduced the 
incidence of clinically significant chemotherapy-induced oral mucositis compared to placebo.[37] 
By comparison, the MASCC/ISOO guidelines recommend that systemically administered 
glutamine not be used for the prevention of GI mucositis because of lack of efficacy.[38] 
6.3 Amifostine 
It (phosphothiorate, radiation protection agent) is thought to act as a scavenger for harmful 
reactive oxygen species that are known to potentiate mucositis.[39] However, because of 
insufficient evidence of benefit, various guidelines could not be established regarding the 
use of this agent in oral mucositis in chemotherapy or radiation therapy patients. The use of 
amifostine has been recommended for the prevention of esophagitis in patients receiving 
chemoradiation for nonsmall-cell lung cancer.[40]  
6.4 RK- 0202 (RxKinetix)  
It consists of the antioxidant, N-acetylcysteine, in a proprietary matrix for topical application 
in the oral cavity. In a placebo-controlled phase II trial in patients with head and neck 
cancer, this agent significantly reduced the incidence of severe oral mucositis up to doses of 
50-Gy radiation therapy.[41] 
6.5 Beta carotene 
Beta carotene, a vitamin A derivative, is a scavenger of singlet oxygen. Based on the findings 
of different randomized controlled study, it is of the view that supplemental dietary beta-
carotene lead to a mild decrease in the severity of chemotherapy and radiotherapy-induced 
oral mucositis.[42] 
7. Immunomodulatory drugs 
7.1 Pentoxifylline 
Oral pentoxiphylline reduced the frequency and severity of all major complications after 
BMT, including reduction of oral mucositis.[43] Contradictory to this, other workers reported 
a significant aggravation of symptoms when they studied the effect of IV Pentoxiphylline in 
92 patients.[44] However, no difference in symptoms was noted in patients who undergone 
chemo radio therapy.  
7.2 Indomethacin 
Indomethacin, a nonsteroidal antiinflammatory drug inhibiting prostaglandin synthesis is 
noted to delay the onset of mucositis. 
7.3 Immunoglobulin 
Treatment with low-dose intra muscular immunoglobulin is said to decrease the severity 
and duration of radio therapy-induced oral mucositis. Immunoglobulin has also been tried 
as a therapeutic agent in radiation-induced mucositis in various clinical trials and the 
observations were promising.[45] 
7.4 Cytokines 
Preclinical models have been used to demonstrate that the cytokines interleukin-1, 
interleukin-2, epidermal growth factor, interleukin-11, and transforming growth factor-beta 
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have direct effect on intestinal or oral mucosa. Interleukin-1 increases thymidine labeling, 
and protects oral and intestinal mucosa, when given to mice before radiation. Interleukin-11 
can decrease mucositis, when given to hamster models. 
7.5 G-CSF, GM-CSF 
The mucosal protection effects of granulocyte colony stimulating factor G-CSF were 
observed in patients treated with various chemotherapy regimens by many authors.[46] But 
controversies to this exist in other clinical trials. In a recent preliminary report of a pilot 
study found significant reduction in oral mucositis.[47] The study was to evaluate the effect 
of GM-CSF in reduction of radiotherapy induced oral mucositis. At about second week of 
radiotherapy, when oral pain was experienced 400 g of GM-CSF was administered locally 
once a day, until completion of radiotherapy. The patients were evaluated weekly for 
mucosal reaction and functional impairment. The result of the study was prompting with 
reduction and almost healing of oral mucositis in 14 out of 17 patients with completion of 
radiotherapy within the preplanned schedule. Moreover patients did not show a significant 
weight loss or functional impairment. 
8. Anti-viral drugs 
8.1 Acyclovir 
Although acyclovir prophylaxis is effective in preventing oropharyngeal shedding of the 
virus in herpes simplex virus seropositive patients receiving intensive chemotherapy or 
BMT, it did not influence chemotherapy, radiotherapy and BMT-related oral toxicity. 
9. Role of safe radiotherapy 
Normal tissue reactions can be reduced in a substantial number of patients with head and neck 
cancer by the use of computed tomography (CT)-based target delineation, Intensity-
Modulated Radiation Therapy (IMRT), and simple, custom-made, intraoral devices that are 
designed to exclude uninvolved tissues from the treatment portals or to provide shielding of 
tissues within the treatment area.[43] Stents can be useful in excluding the palate mucosa during 
treatment of the tongue or floor of the mouth. These shielding stents can decrease the amount 
of radiation that is delivered to the contra-lateral mucosa. More frequent use of electron-beam 
and/or sophisticated three-dimensional conformal, multibeam, wedged-pair, or oblique 
treatment plans will also help to exclude or minimize the radiation dose to uninvolved 
mucosa. Packing gauze between metallic dental restorations and mucosa of the lateral tongue 
and buccal area appears to be very beneficial in minimizing the dose from scattered radiation. 
9.1 Antifungal therapy 
The mucosa of patients undergoing radiation therapy to the oral cavity should be examined 
at least once a week, and antibiotic or antifungal medications should be prescribed when 
infections are documented. Clotrimazole troches, dissolved in the mouth five times a day for 
14 days, generally works well for oral candidiasis. However, if significant mucositis, altered 
taste, or xerostomia has developed, the troches might not be tolerated. In this situation, 
nystatin oral suspension or Fluconazole in tablet or liquid form is often effective. 
Fluconazole is more effective than nystatin and might need to be given at a higher dose 
and/or for an extended period of time in patients who are receiving combined 
chemotherapy and radiation therapy due to infections with resistant species.[48] 
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9.2 Low-level laser therapy 
The mechanism of low-level laser therapy is not understood, but many studies have proved 
the efficacy of the same in reducing the symptoms related to oral mucositis. Low-level laser 
therapy may reduce levels of reactive oxygen species and/or proinflammatory cytokines 
that contribute to the pathogenesis of mucositis.[49] The various guidelines suggest the use of 
low-level laser therapy for reducing the severity of chemotherapy and radiotherapy-
induced oral mucositis.[50]  
9.3 AMP-18 (Antral mucosal protein) 18 
A study on AMP18 (AMP-18 is a protein constitutively expressed in epithelial cells of the 
gastric antrum that is cell protective, mitogenic and motogenic in cell culture and in vivo) 
shows, AMP peptide, by activating CCKBR (cholecystokinin-B/gastrin receptor), targets 
TJs(Tight Junctions) to maintain mucosal integrity, and sets in motion protective and cell 
regenerative mechanisms for the prevention and treatment of OM. Treatment with AMP 
peptide protected the surface epithelium of the mouse oral mucosa. AMP-18 peptide 
stimulates growth of diverse types of epithelial cells including HaCaT cells [54]. 
10. Summary  
Mucositis is an inevitable side effect of radiation. The severity of the mucositis depends on 
the type of ionizing radiation, the volume of irradiated tissue, the daily dose, and the 
cumulative dose. As the mucositis becomes more severe, pseudomembranes and ulcerations 
develop. Poor nutritional status further interferes with mucosal regeneration by decreasing 
cellular migration and renewal. Radiation-induced oral mucositis affects the quality of life of 
the patients and the family concerned. The present day management of oral mucositis is 
mostly palliative and or supportive care. Management includes good oral hygiene, avoiding 
irritating or abrasive substances, use of bland rinses, topical anesthetic agents, and systemic 
analgesics. Though, the newer guidelines are suggesting Palifermin, which is the first active 
mucositis drug as well as Amifostine, for radiation protection and cryotherapy for 
symptoms related to high-dose melphalan; the role of safe radiotherapy remains the 
ultimate goal in reducing the symptoms of radiation-induced oral mucositis. Future 
research for the newer drugs in the field of radiation-induced oral mucositis is a must, and 
the current management should focus more on palliative measures, such as pain 
management, nutritional support, and maintenance, of good oral hygiene. 
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